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1. Introduction 
Prolactin (PRL) is a polypeptide hormone secreted by the anterior pituitary responsible for the 
growth and differentiation of the normal mammary gland and plays a role in breast cancer. It 
functions systemically as an endocrine factor, but PRL may also act in an autocrine/paracrine 
fashion in a number of other tissues. Studies in both pre- and post-menopausal women have 
determined a significant increased risk for breast cancer for those with serum PRL in the 
highest quartile [6, 7]. PRL, acting through its receptors, has been shown to increase cell 
proliferation and decrease apoptosis in breast cancer cells in vitro [3, 8]. PRL also acts as a pro-
angiogenic factor in mammary tissues [9]. PRL exerts its effects by binding to its receptors on 
the surface of normal human breast epithelial and cancer cells, initiating the Jak2/Stat5, PI3K, 
and mitogen-activated protein kinase (MAPK) signaling pathways [3]. 
The PRL receptor (PRLR) is a member of the class I cytokine/hematopoietic receptor 
superfamily. A single hydrophobic transmembrane region separates the extracellular 
ligand-binding domain from the intracellular signaling domain. Five cell-associated PRLR 
isoforms differ only in their C-terminal cytoplasmic domains [1, 3]. The three major isoforms 
(long, LF; short 1a and 1b, SF1a and SF1b, respectively) are regulated by PRL itself. LF 
signals for many functions including growth and differentiation, whereas SF1a and SF1b act 
as dominant-negatives for differentiation [1, 2]. The role of the short forms in breast cell 
growth remains to be determined. 
2. Problem statement 
Studies from our laboratory [1] and from others [2] have demonstrated that three specific 
isoforms of the PRLR are expressed in both normal and cancerous breast cells and tissues. 
We recently developed and characterized PRLR isoform specific polyclonal antibodies that 
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revealed that the three isoforms, LF, SF1a, and SF1b, are differentially expressed in ductal 
and lobular carcinomas [5]. These two most common histological types of breast cancer 
originate from the terminal ductal lobular unit and may be difficult to classify. However, 
distinct differences were observed in PRLR expression in normal, benign, and malignant 
breast tissue which may have prognostic significance [10, 11]. The development and 
characterization of PRLR isoform specific monoclonal antibodies will provide a near 
limitless supply of reagent to continue to examine how and where these isoforms interact 
both in normal breast development and in breast cancer. 
3. Application area  
The identification of estrogen receptor (ER) and progesterone receptor (PR) in the current 
testing of breast cancer has advanced the field. Other hormones/growth factors are also 
involved; for example, PRL and its receptor isoforms. If their roles are more clearly 
identified with the use of specific antibodies then there may be a practical need for them in 
the diagnosis of this disease. Examining normal breast development could give clues to the 
relevance of PRLR isoforms in cancer. Not only do these apply to the breast, but may also be 
of value to studying ovarian and prostate cancers where PRL may play a role/function. 
PRLR isoform specific antibodies could be powerful tools in this quest. 
4. Methods 
4.1. Preparation of the PRLR isoform specific monoclonal antibodies 
Synthetic peptides were designed based on the regions of unique intracellular sequences of 
the PRLR splice variants and synthesized (AnaSpec, Inc., San Jose, CA) by the solid-phase 
method. Peptides (4 mg) were conjugated to bovine serum albumin (10 mg) with 1mM DSS 
overnight at room temperature and sent to Epitomics (Burlingame, CA) for immunization of 
rabbits. Initially, a total of 76 clones were received (54 clones for SF1a, 22 clones for SF1b) 
and screened for reactivity to their respective antigens by Western blot analysis. Briefly, 
lysates of CHO-K1 cells expressing either SF1a or SF1b were separated by SDS-PAGE, and 
transferred to PVDF. Membranes were blocked for 1 hr at room temperature in 5% non-fat 
dairy milk diluted in TBST+0.1% sodium azide. Subsequently, the clonal supernatants were 
diluted 1:1 in 10% non-fat dairy milk (diluted in TBST+0.1% sodium azide) and incubated 
for 3 hr at room temperature. Membranes were washed and probed with goat anti-rabbit 
Alexa680 (1:4000) prior to visualization using a LiCOR Odyssey reader. Supernatants from 
positively reacting clones were re-screened prior to selection for subcloning. In total, four 
SF1a and six SF1b rabbit monoclonal antibodies were put into production. The rabbit sera 
were initially purified by MEP Hypercel (PAL) chromatography, followed by size-exclusion 
chromatography to further purify the antibodies. Final pools of antibody were produced 
and protein concentration determined by the Pierce 660nm assay. 
For LF, 6 mg peptide was conjugated to 3 mg keyhole limpet hemocyanin overnight at room 
temperature using glutaraldehyde. Peptide conjugates were sent to Green Mountain 
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Antibodies (Burlington, VT) for generation of mouse monoclonal antibodies. Initially, 120 
clones were screened by Western blot as described above using CHO-K1 cells expressing LF 
with the exception that the antibodies were diluted 1:100 in 5% non-fat dairy milk (diluted 
in TBST+0.1% sodium azide) and incubated overnight at 4o C. Secondary antibody and 
imaging were essentially as described above. Supernatants of positively reacting clones 
were re-screened by Western blot and examined by fluorescence microscopy (to confirm 
appropriate localization) prior to selection for production. In total, 10 positive clones were 
selected for this process, 8 of which produced IgG. Antisera was purified as described for 
SF1a and SF1b antibodies. Final pools of antibody were produced and protein concentration 
determined by the Pierce 660nm assay. 
4.2. Cell culture and transfection  
Chinese hamster ovary cells (CHO-K1, ATCC, Manassas, VA) were maintained in -MEM 
(Invitrogen, Gaithersburg, MD) supplemented with 5% fetal bovine serum (FBS, Invitrogen) 
and penicillin/streptomycin (100 U/ml and 100 g/ml respectively, Invitrogen). Transfections 
were performed using FuGENE 6 (Roche Applied Science, Indianapolis, IN) at a ratio of 1 
g DNA to 3 l FuGENE. The PRLR isoform specific cDNA constructs were previously 
described [1]. Cells were transfected for 48 hr, then allowed to grow for an additional 48 hr.  
T47D, ZR75-1, MDA-MB-231, MDA-MB-468, MCF7, and SK-BR-3 breast cancer cell lines 
were obtained from ATCC. T47D, ZR75-1, MDA-MB231, and MDA-MB468 cells were 
maintained in RPMI1640 (Invitrogen). MCF7 cells were grown in DMEM and SK-BR-3 cells 
were maintained in McCoys 5a media. All media were supplemented with 5% heat inactivated 
FBS, 10 g/ml bovine insulin (Sigma, St. Louis, MO), and penicillin-streptomycin (100 U/ml 
and 100 g/ml respectively, Invitrogen). Where indicated, breast cancer cell lines were plated 
on 8-well glass chamber slides (Nunc, Rochester, NY) in normal growth media, and allowed 
to attach overnight. The media were replaced and the cells were treated for the indicated 
times with 500 ng/ml recombinant human PRL in media where the FBS was replaced with 
1% charcoal stripped serum, then fixed in 10% normal buffered formalin prior to Duolink 
assay. 
All cells were maintained at 37 °C in a humidified atmosphere with 5% CO2. Cells were 
passaged using trypsinization (0.05% trypsin-EDTA, Invitrogen) and counted on a 
hemocytometer using trypan blue exclusion 
4.3. Western blot analysis  
Transfected CHO cells were collected and whole cell lysates were prepared in Complete 
Buffer (Roche Applied Science) according to the manufacturer’s instructions. Total protein 
was estimated according to Bradford [12]. Protein (100 g) was subjected to 10-20% SDS-
PAGE (Invitrogen). Proteins were transferred to nitrocellulose membrane and probed with 
PRLR isoform specific antibodies (10 g/ml for LF, 6 g/ml for SF1a or SF1b). Reactivity was 
detected using ECL Plus (GE Healthcare Life Science, Pittsburgh, PA). Molecular size 
determinations were made using BenchMark Protein Ladder (Invitrogen). 
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4.4. Fluorescent immunocytochemistry 
CHO cells were plated on 8-well glass chamber slides (Nunc) and transfected as above. 
After blocking with 5% normal goat serum (Jackson Laboratories, Bar Harbor, ME) prepared 
in PBS-0.1% Triton, slides were incubated with the PRLR isoform specific monoclonal 
antibodies (10 g/ml for LF, 6 g/ml for SF1a or SF1b) overnight at 4o C. In all cases no 
primary antibody served as the negative control. Slides were washed four times with PBS-
0.1% Triton followed by incubation for 1 hr with either red fluorescent tagged goat anti-
mouse secondary antibody for the PRLR-LF or red fluorescent tagged goat anti-rabbit 
secondary antibody for the PRLR-SF (AlexaFluor 594, 1:500, Invitrogen) in the dark. After 
extensive washing with PBS containing Triton, slides were mounted with Prolong Gold 
antifade reagent with DAPI (Invitrogen). The fluorescent staining pattern of the receptor 
isoforms was evaluated using an Olympus BX40 fluorescence microscope (Olympus 
America, Center Valley, PA). 
4.5. Fluorescent immunohistochemistry  
Fresh breast samples were supplied by either the Cooperative Human Tissue Network, a 
NCI supported resource that supplies human biospecimens to IRB approved researchers, or 
from patient samples collected in accordance with the guidelines of the National Cancer 
Institute Review Board, protocol 02-C-0144. Breast tissue was obtained from 15 pre-
menopausal reduction mammoplasty patients; each sample was determined free from 
hyperplastic growth by a pathologist. Samples were fixed in 10% normal buffered formalin, 
embedded, cut into four micron sections, deparaffinized, and stained as above. For dual 
labeling studies, sections were incubated overnight at 4o C with LF (10 g/ml) and either 
SF1a or SF1b (6 g/ml) monoclonal antibodies. Red fluorescent anti-mouse secondary 
antibody (AlexaFluor 594, 1:500) was used for LF; green fluorescent anti-rabbit secondary 
antibody (AlexaFluor 588, 1:500) was used for SF1a and SF1b. 
An additional eight samples were also snap-frozen and stored at -80o C for OCT embedding 
and sectioning. Frozen tissue sections were thawed for 30 to 60 sec and fixed in ice-cold 
methanol:acetone (1:1) for 10 min. After washing twice with PBS, sections were blocked for 
30 min with 10% normal goat serum in IF buffer (PBS containing 0.05 mg/ml sodium azide, 
0.1 mg/ml BSA, 0.02% Triton X, and 0.05% Tween 20). Sections were incubated with either 
LF (10 g/ml) and SF1a or SF1b (6 g/ml) PRLR isoform specific monoclonal antibodies 
overnight at 4o C. Sections were extensively washed with PBS, then incubated with red 
fluorescent anti-mouse secondary antibody (AlexaFluor 594, 1:500) for LF and green 
fluorescent anti-rabbit secondary antibody (AlexaFluor 588, 1:500) for SF1a and SF1b. 
Sections were washed again and mounted with Prolong Gold antifade reagent with DAPI.  
The fluorescent staining patterns of the PRLR isoforms were assessed using an Olympus 
BX40 fluorescent microscope. For both paraffin-embedded and frozen tissue sections, 
photographs were immediately taken under the violet, green, and blue channels to detect 
DAPI, red, and green fluorescence, respectively. Images were merged in order to observe 
PRLR isoform localization patterns.  
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Nine samples of paraffin-embedded breast tumor tissue were stained and analyzed as 
above. 
4.6. Measurement of fluorescence intensity  
Because serial sections for the breast specimens were used, the same region of each tissue 
could be measured for fluorescence intensity using Adobe Photoshop (Adobe Systems Inc., 
Beaverton, OR). Nearly every cell in positive samples showed some level of PRLR isoform 
expression; as a result, red fluorescence intensity was used to compare levels of isoform 
expression between samples. In order to do this, the same fluorescent areas were selected 
from each serial section using the lasso and rectangular marquee tools. Selected sections 
were analyzed using the histogram function through the red channel, which gave the mean 
red intensity of the selected section. Photoshop assigns intensity values between 0 and 255 
to each pixel in the selected area and then averages these intensities. The distribution of 
these means was analyzed and used to divide samples into four intensity classes: negative 
(less than 10 intensity), low (between 11 and 30 intensity), medium (between 31 and 50 
intensity), and high (greater than 51 intensity).  
4.7. Generation of ProbeMaker probes for Duolink  
Antibodies against the various PRLR isoforms were directly conjugated using the 
ProbeMaker protocol as described by the manufacturer (OLINK BioScience, Upsala, 
Sweden). Briefly, 2 l ProbeMaker conjugation buffer was added to 20 g of each antibody 
(starting antibody concentration, 1 mg/ml) prior to addition of the antibody to the 
lyophilized oligonucleotides (PLUS and MINUS probes). Incubation with oligonucleotides 
proceeded overnight at room temperature, followed by addition of 2 l of ProbeMaker Stop 
Reagent and incubation for 30 min at room temperature to conclude the labeling reactions. 
Unreacted oligonucleotides were rendered inactive during this step, preventing spurious 
signals from being generated. For storage of the antibody-oligonucleotide conjugates, 24 l 
ProbeMaker storage buffer was added. The final concentration of the antibody-
oligonucleotide conjugates were ~0.4 mg/ml and stored at 4o C until use. 
4.8. In situ proximity ligation assay  
Cultured cells were plated onto 8-well chamber slides (Millipore) in media for one day prior 
to stimulation as described above. Cells were stimulated for 0, 5, 10, or 60 min with PRL, 
washed twice in PBS, then fixed in 4% paraformaldehyde for 10 min. Fixed cells were 
subsequently washed twice with PBS, dried and frozen at -20o C.  
On the day of the experiment, slides were thawed at room temperature and rehydrated in 
PBS for 10 min at room temperature. All steps of the Duolink protocol were performed as 
open droplet reactions on the chamber slides, using 30 l volume per chamber to ensure 
complete coverage of the cells. Cells were then permeabilized in PBS+0.1% Triton X-100 for 
10 min at room temperature, washed twice in PBS, and blocked in 1X Duolink Blocking 
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solution for 30 min at 37o C in a humidity chamber to prevent evaporation. PRLR primary 
antibody-oligonucleotide conjugates were diluted in PLA Probe Diluent to 5 g/ml, and 
applied to slides overnight at 4o C in a cooled humidity chamber. On the second day, slides 
were washed 3 times in 1X Duolink Wash Buffer A to remove excess antibody-
oligonucleotide conjugates. Bound antibody-oligonucleotide conjugates were ligated 
together for 30 min at 37o C according to the manufacturer’s instructions. Subsequently, 
ligated templates were amplified for 2 hr at 37o C according to the manufacturer’s protocol, 
washed twice for 10 min in Duolink 1X Wash Buffer B, and once for 1 min in 0.1X Wash 
Buffer B prior to mounting with Duolink Fluorescence mounting media (which also contains 
DAPI for nuclear counterstaining) and observation under a fluorescent microscope. 
Image acquisition was performed using a Zeiss Axioscope M1 under 40X magnification and 
an AxioCam HR. Image analysis was performed using the Duolink ImageTool software 
according to the instructions provided by OLINK. 
5. Results 
5.1. Characterization of PRLR isoform specific monoclonal antibodies 
We have recently prepared and characterized PRLR isoform specific polyclonal antibodies 
[5]. However, a limitless source of polyclonal antibody is restricted because it is generated 
by repeated immunization of a rabbit. Each antibody preparation has the potential to vary in 
its specificity as well. Monoclonal antibodies are more homogeneous and can produce a 
near inexhaustible supply of reagent. We used the same peptide sequence as for the 
preparation of isoform specific polyclonal antibodies and, again, demonstrate specificity for 
the individual isoforms. CHO cells were transiently transfected with cDNA containing the 
individual PRLR isoforms; western blot analysis from cell lysates indicate that the 
antibodies detect the corresponding protein without cross-reactivity (Figure 1A).  
By immunocytochemical analysis using transiently transfected CHO cells, we were able to 
positively stain for isoform specific PRLR. As shown in Figure 1B, no cross-reactivity was 
identified using the antibodies on cells transfected with non-corresponding PRLR cDNA. By 
both western and immunochemical analysis we were able to demonstrate the specificity of 
the PRLR isoform specific monoclonal antibodies. 
5.2. Immunofluorescent staining of human breast tissue  
Once we determined the specificity of the isoform specific monoclonal antibodies on 
transfected cells, we tested them on histosections obtained from reduction mammoplasty 
specimens. In order to examine the localization patterns of the PRLR, we stained the tissues 
simultaneously with LF and either SF1a or SF1b antibodies. Similar, striking, distribution of 
isoform expression was observed, regardless of whether paraffin-embedded or frozen 
sections were used. As seen in Figure 2, LF expression appeared primarily basal, whereas SF 
localized more luminally. 
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Figure 1. Characterization of PRLR isoform antibodies. A. Western blot analysis indicating specificity of 
monoclonal antibodies. CHO cells were transiently transfected with isoform specific PRLR cDNA as 
described. Cell lysates were prepared and proteins separated by PAGE. Each isoform specific lysate was 
probed with each isoform specific antibody. Western blot analysis was performed twice with separate 
lysates. Data shown are a representative autoradiogram. Molecular weights are marked as indicated: LF 
= 93kDa, SF1a = 55kDa, SF1b = 43kDa. B. Fluorescent immunocytochemical analysis. CHO cells were 
transiently transfected with isoform specific PRLR cDNA as described. Specific staining was observed. 
The negative control lacks primary antibody. Data shown are representative of triplicate experiments. 
Magnification 20X. 
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Figure 2. Fluorescent immunohistochemical analysis from normal breast tissues. Representative photos 
taken from breast reduction mammoplasty specimens. Images in left panels are taken from paraffin 
embedded tissues; middle panels are imaged from frozen sections; right panels are taken from paraffin 
embedded normal lactating mammary tissues. Negative control indicates no primary antibody used. LF 
is indicated by green fluorescence; SF is indicated by red fluorescence. LF = long form; SF = short form. 
Magnification 40X. 
However, the expression patterns localized quite differently in cancer tissue. The PRLR 
isoforms appeared to colocalize, but were only present in specific areas (Figure 3). The 
pattern seemed more random, concentrated in “hot spots,” particularly for SF1a. 
5.3. In situ proximity ligation assay monitors PRLR dimerization  
The Duolink reagents allow for specific protein-protein interactions to be examined in situ. 
Using antibodies to PRLR-LF, SF1a and SF1b we generated PRLR isoform-specific PLA 
probes in order to monitor every possible dimer combination using the OLINK ProbeMaker 
kit. This kit allows for the direct conjugation of the oligonucleotide (PLUS or MINUS end) to 
the primary antibody, which is essential for examining homodimers. Using these probes, we 
examined the six possible dimer pairings (LF/LF, SF1a/SF1a, SF1b/SF1b, LF/SF1a, LF/SF1b, 
SF1a/SF1b) in six established breast cancer cell lines: T47D, ZR75-1, MDA-MB-231, MDA-
MB-468, MCF7, and SK-BR-3 in the absence and presence of PRL stimulation. In addition to 
the specific antibodies, we included non-specific isotyped control antibodies as negative 
controls (i.e. LF/NSR, where NSR is a non-specific rabbit IgG in place of a specific rabbit 
antibody against PRLR). After the proximity ligation reaction has taken place, a single 
fluorescent red dot is observed. This dot represents a single molecular interaction between 
the two proteins being interrogated.  
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Figure 3. Fluorescent immunohistochemical analysis from breast cancer tissues. Representative photos 
taken from breast tumor specimens. LF is indicated by green fluorescence; SF is indicated by red 
fluorescence. LF = long form; SF = short form. Magnification 40X. 
With the exception of the MDA-MB-231 cells, similar patterns of expression were observed 
in all breast cell lines tested. In the ER positive MCF7 cells, dimers of all six potential 
combinations were observed in the absence of stimulation, and were maintained throughout 
the stimulation with PRL (Figure 4A). However, in the ER negative MDA-MB-231 cells, a 
much more complex pattern appeared (Figure 4B). We observed changes in the levels of 
several dimers over the course of PRL stimulation, suggesting that the different dimer 
pairings may be utilized by the cell to mitigate responses to prolonged PRL stimulation.  
While performing these experiments, we noticed a significant amount of PRLR dimers at 
either the perinuclear or nuclear region of the cell. Several receptors in the mammary gland 
have been shown to undergo nuclear translocation including EGFR, FGFR, and GHR [13]. 
However, there is little information known about the nuclear localization of PRLR. Several 
reports in the literature have offered contradicting evidence for PRLR nuclear translocation 
[19-21].  
In a preliminary study of PRLR isoform nuclear translocation, MDA-MB-231 cells were 
stimulated with PRL  
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Figure 4. Duolink analysis of breast cancer cell lines for PRL-dependent PRLR dimerization. 
Representative images are shown for each dimer pairing in both MCF7 (panel A) and MDA-MB-231 
(panel B) cells at 0, 5, 10 and 60 min post-stimulation with PRL. Magnification 40X. Nuclei stained 
(shown in blue) with DAPI, Duolink signal shown in red. Each red dot represents a single dimerization 
event. 
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6 hr prior to Duolink analysis to examine steady-state nuclear localization of PRLR dimer 
formation using confocal microscopy (Figure 5). Of the various combinations of PRLR 
isoform dimers that were examined, nearly all exhibited some nuclear localization. The 
exception was for SF1a/SF1a homodimers, which formed perinuclear rings but showed little 
to no nuclear localization (Figure 5B). Homodimers of the two short forms or a heterodimer 
of the two short forms (Figure 5B, SF1a/SF1a; Figure 5C SF1b/SF1b; Figure 5D, SF1a/SF1b) 
exhibited significantly higher levels of nuclear localization while LF homodimers (Figure 
5A) and the two LF-short form heterodimers (Figure 5E, LF/SF1a; Figure 5F, LF/SF1b) 
showed modest levels of nuclear localization. These results confirm that nuclear 
localization exists for the human prolactin receptor isoforms and may suggest a new role 
for them as potential transcriptional regulators. Pathways indicating the intranuclear 
transport and function of PRL and its receptor targeting intracellular actions, such as 
transcription, have been demonstrated [13]. Increases in transcription may effect cell 
proliferation and/or differentiation. However, the function of perinuclear localization has 
yet to be explored. 
 
 
Figure 5. PRLR isoform dimers exhibit different localization patterns. MDA-MB-231 cells were 
stimulated for 6 hr with 500 ng/ml recombinant human PRL, fixed and examined by confocal 
microscopy for PRLR dimer localization using Duolink. Dimer combinations: A. LF/LF; B. SF1a/SF1a; C. 
SF1b/SF1b; D. SF1a/SF1b; E. LF/SF1a; F. LF/SF1b. Images were acquired using a 20X objective with a 2X 
zoom. 
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6. Discussion and further research  
Prolactin signaling through the LF of the PRLR has been well studied [13]. Two short forms 
of the PRLR (SF1a and SF1b) share common extracellular and transmembrane domains with 
the LF, yet contain different cytoplasmic sequences due to alternative splicing of exon 11 
[1,2]. The role of these short forms in PRLR function remains elusive, in part due to a lack of 
specific reagents. Both SF1a and SF1b contain the Box1 binding site for Jak2 and MAPK 
proteins, yet lack the Box 2 site (and downstream phosphorylation sites) required for STAT 
binding [2, 14]. By lacking part of intracellular signaling domain, the short forms of the 
PRLR act as dominant negatives of the LF in transfected cells and its effects most likely 
occur through heterodimerization with LF [5]. While both short forms can function as a 
dominant negative, SF1b is the more potent negative regulator of LF function. 
To facilitate the study of the PRLR short forms, we generated isoform-specific polyclonal 
antibodies and demonstrated a breast cancer specific pattern of expression. While all tumor 
biopsies expressed both LF and SF1b equally, the presence of SF1a was detected mainly in 
ductal breast carcinoma biopsies and not in those derived from lobular carcinomas [5]. 
These data suggest diagnostic potential for the PRLR short forms.  
The mere expression profiles of these proteins may not serve as sufficient biomarkers, as 
PRLR dimers are the functional unit for PRL-mediated events. Therefore, an analysis of the 
ratios of the various potential dimers may be needed to generate a more complete 
understanding of PRLR signaling. Techniques such as BRET and FRET have been used to 
examine PRLR dimer formation [14-17]. However, these techniques collectively constrain 
the user to cells that express tagged constructs and prevent analysis of tissue samples. Co-
immunoprecipitation has been used with moderate success for PRLR dimer analysis and 
avoids the need for tagged constructs, but lacks quantitation, requires specific antibodies, 
and is devoid of any cellular localization information. To overcome these technical 
challenges, we employed an in situ proximity ligation assay developed by OLINK. This 
technique allows for the sensitive detection of protein-protein interactions in unmodified 
cells and tissue. Using the newly generated rabbit and mouse monoclonal PRLR isoform-
specific antibodies, we examined PRLR dimer formation in breast cancer cell lines in the 
absence and presence of PRL stimulation. Due to the flexibility of the method, we were able 
to monitor all possible homo- and hetero-dimers concurrently.  
We were able to confirm that PRLR homo- and hetero-dimers form in the absence of PRL, 
similar to reports by others [14, 17]. Similar reports have shown that members of the EGFR 
family can form dimers in the absence of ligand [18]. In total, we observed homodimers of 
LF/LF, SF1a/SF1a, and SF1b/SF1b and heterodimers of LF/SF1a, LF/SF1b, and SF1a/SF1b in 
two different, but well-established breast cancer cell lines, MCF7 and MDA-MB-231. While 
SF homodimerization has been shown, heterodimerization of the short forms has been 
examined but not proven [16]. However, these assays utilized PRLR receptors C-terminally 
tagged with GFP or Rluc to perform BRET analysis, which may somehow block the 
detection of the SF heterodimer. The functional consequence of the SF1a/SF1b heterodimer is 
not known. Given that both short forms lack the majority of the intracellular domain, this 
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dimer may be formed to limit the inhibitory activity of each monomer towards the LF by a 
yet-to-be discovered mechanism. 
In addition to confirming the existence of all possible dimer pairings, we were able to show 
that the different PRLR dimers peaked at different times during the PRL time course. These 
data suggest that upon stimulation with PRL, regulatory events occur within the cell to 
favor a particular signaling outcome. For example, an increase in LF/SF1b dimers is 
predicted to sequester otherwise functional LF monomers into inactive dimers with SF1b. 
These dimers (and similarly LF/SF1a dimers) would be capable of binding PRL, but would 
most likely be unable to transmit the signal from ligand binding to the intracellular milieu. 
Thus, the dominant negative nature of the PRLR short forms could occur by isolating PRLR 
LF monomers and also result in diminished effects of PRL on cells. Further studies would be 
required to better understand the dimerization time course for PRLR in these and other 
breast cancer cell lines. 
The confirmation of the nuclear localization of PRLR dimers is an important finding. 
Conflicting reports were found in the literature [13, 19, 20], however our study confirms that 
PRLR dimers can be found in the nucleus of cultured breast cancer cells. Interestingly, the 
amount of nuclear localized PRLR was different for the various dimer pairings tested in 
MDA-MB-231 cells. In general, the SF dimer combinations (SF1a/SF1a, SF1a/SF1b, and 
SF1b/SF1b) exhibited higher levels of nuclear localization than dimers containing at least 
one monomer of LF. In addition, only SF1a homodimers localized to a perinuclear region, 
and appeared as rings around the nucleus. Together these data suggest a potential 
transcriptional role for PRLR. Recent work performed in the Walker laboratory [21] 
demonstrated that, in prostate cancer, the expression of SF1b was upregulated after 
treatment with the PRL inhibitor S179D. This increase in repression also led to an 
upregulation of p21 and the vitamin D receptor (VDR), both known to affect differentiation 
and apoptosis. In vitro studies also confirmed that long-term overexpression to SF1b 
decreased the growth and migration of prostate cancer cells, in addition to enhancing cell-
matrix interactions and cell-cell aggregation [22]. Abnormalities in the vitamin D endocrine 
system have been linked to many disorders, including cancer [23]. Strong epidemiological 
associations were made between vitamin D deficiency and breast and prostate cancers. The 
VDR system may arrest the tumor cell cycle at G1/G0 through several mechanisms such as 
by induction of p21 gene transcription [24] or by inducing the synthesis and/or stabilization 
of p27 [25]. Recent work in tumor-derived endothelial cells has implicated VDR as an anti-
proliferative factor inducing cell cycle arrest in G1/G0 and tumor angiogenesis [26]. Loss of 
VDR in this system or in mammary epithelial cells may affect differentiation and apoptosis 
or modulate intracellular signaling routes. These changes in the tumor microenvironment 
could potentially result in aberrant angiogenic signaling pathways, possibly even enhancing 
angiogenesis for a more efficient delivery of chemotherapeutic drugs. PRL and its signaling 
pathways could be exploited to search for more effective therapies in prostate and breast 
cancer [27]. Potential synergy with various chemotherapeutics may be another aspect of the 
importance of dimerization and localization of PRL and its receptors in breast cancer. 
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As discussed herein, our laboratory has recently published the utility of PRLR isoform-
specific antibodies in characterizing breast cancer samples as either lobular or ductal in 
nature [5]. The generation of monoclonal antibodies to the various PRLR isoforms provides 
a more renewable and reliable supply of these antibodies, and were crucial to the 
dimerization studies. To our knowledge, this is the first time that the Duolink in situ 
proximity ligation assay enabled detection of all possible PRLR dimer combinations. The 
technique is robust, quantitative and relatively easy to use.  
With the advent of the tissue microarray (TMA) [28, 29], researchers are able to examine 
large populations of tissues from patients on a single glass slide. There are many 
commercially available TMAs as well, including arrays for breast cancer patients. These 
arrays have typically been evaluated for ER/PR/HER2 status and, in many cases, have both 
normal and diseased tissue for each patient. Given that OLINK provides a Brightfield 
Duolink kit, several studies could be envisioned. First, since the Duolink assay can also be 
used to obtain quantitative total expression of a target, the application of this technique to 
TMAs would provide a significantly better means of analyzing the expression levels of 
targets (rather than high, medium, and low expression). These data could also be combined 
with expression profiles of the PRLR dimer complexes and ultimately compared with other 
markers to identify more specific breast cancer signatures. Further correlations could be 
made with the levels of the hormone PRL itself, which could help further diagnose patients. 
The “hormonal responsiveness” of breast cancer has been known for a long time. 
Unfortunately, this phrase has only been used to indicate responsiveness to estrogen (E) and 
progesterone (P). However, several other hormones including PRL, growth hormone, and 
thyroid hormone have been shown to play roles in normal breast development and function 
and their various roles in breast cancer are being investigated. The complex interplay of the 
three major hormones involved in normal breast development, E, P, and PRL, is well 
documented. In model systems that include human breast cancer cells in culture as well as 
rodent models, E, P, and PRL have all been shown to stimulate growth. In fact, when 
compared directly with E acting on MCF-7 human breast cancer cells, PRL is a more potent 
mitogen than E [8]. 
Additionally, these model systems have demonstrated that each of these hormones acts as 
more than just a mitogen. Complex systems of inter-regulation exist between these steroids, 
PRL and their receptors. PRL stimulates growth through both an endocrine as well as an 
autocrine/paracrine mechanism. The expression of autocrine PRL in human breast cancer 
cells is regulated by E through action on the PRL promoter [30]. Expression of the PRL gene 
is regulated by two promoters, the proximal promoter utilized primarily in the pituitary and 
the distal promoter utilized in breast cancer cells. E directly induces hPRL gene expression 
in T47D human breast cancer cells through the action of a functional non-canonical E 
response element (ERE) and an AP1 site on the distal promoter. Both the ERE and AP1 sites 
are required for full induction of promoter activity through the alpha form of the ER. 
Similarly, the interplay of P and PRL is well established in various models. PR and PRLR are 
co-expressed temporally and spatially in the developing mouse mammary gland. In 
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mammary glands from ovariectomized female mice lacking both E and P, neither P nor PRL 
stimulate DNA synthesis in epithelial or adjacent stromal cells. However, simultaneous 
injection of P and PRL results in a significant synergistic effect on DNA synthesis in both cell 
types [31]. Similarly, disruption of expression and distribution of PR in the mammary gland 
results in a parallel disruption of expression and distribution of the PRLR suggesting inter-
regulation of these receptors [32]. Expression of the PRLR in human cells is regulated 
through a complex system of promoters. The PRLR gene in humans has six exon 1s, the 
most generic of which (PRLR promoter region III) is functional in human breast cancer cells. 
T47D human breast cancer cells treated with P overexpress the PRLR and activate PRLR 
promoter III. This promoter lacks a classical P response element. Thus P acts through the 
cooperative interaction of the PR with the transcription factors C/EBP and an adjacent Sp1A 
site to confer P responsiveness leading to increased expression of the PRLR [33]. 
These examples of the complex interactions of E, P, and PRL underscore the importance of 
understanding all three hormones’ actions and their receptor interactions, distribution, and 
functions in the normal human breast and in breast cancer. Effective tools for these studies 
are now available. 
7. Conclusion 
Just as the identification of the ER and PR are now routinely performed on all clinical breast 
cancer samples, screening for PRLR status and isoform profile may also one day become a 
routine procedure in the characterization of breast cancers. Isoform specific antibodies to the 
PRLR can be powerful tools in detection and characterization of breast and other cancers 
and provide valuable insights into the important PRLR signaling pathways that could be 
effective targets for prevention and treatment. 
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